Standard Standard

Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis. / Sandoo, A; Dimitroulas, T; Veldhuijzen van Zanten, J J C S; Smith, J P; Metsios, G S; Nightingale, P; Stavropoulos-Kalinoglou, A; Kitas, G D.

In: Clinical and Experimental Rheumatology, Vol. 30, No. 3, 14.03.2012, p. 388-96.

Research output: Contribution to journalArticle

HarvardHarvard

Sandoo, A, Dimitroulas, T, Veldhuijzen van Zanten, JJCS, Smith, JP, Metsios, GS, Nightingale, P, Stavropoulos-Kalinoglou, A & Kitas, GD 2012, 'Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis', Clinical and Experimental Rheumatology, vol. 30, no. 3, pp. 388-96.

APA

Sandoo, A., Dimitroulas, T., Veldhuijzen van Zanten, J. J. C. S., Smith, J. P., Metsios, G. S., Nightingale, P., ... Kitas, G. D. (2012). Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 30(3), 388-96.

CBE

Sandoo A, Dimitroulas T, Veldhuijzen van Zanten JJCS, Smith JP, Metsios GS, Nightingale P, Stavropoulos-Kalinoglou A, Kitas GD. 2012. Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology. 30(3):388-96.

MLA

VancouverVancouver

Sandoo A, Dimitroulas T, Veldhuijzen van Zanten JJCS, Smith JP, Metsios GS, Nightingale P et al. Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology. 2012 Mar 14;30(3):388-96.

Author

Sandoo, A ; Dimitroulas, T ; Veldhuijzen van Zanten, J J C S ; Smith, J P ; Metsios, G S ; Nightingale, P ; Stavropoulos-Kalinoglou, A ; Kitas, G D. / Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis. In: Clinical and Experimental Rheumatology. 2012 ; Vol. 30, No. 3. pp. 388-96.

RIS

TY - JOUR

T1 - Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis

AU - Sandoo, A

AU - Dimitroulas, T

AU - Veldhuijzen van Zanten, J J C S

AU - Smith, J P

AU - Metsios, G S

AU - Nightingale, P

AU - Stavropoulos-Kalinoglou, A

AU - Kitas, G D

PY - 2012/3/14

Y1 - 2012/3/14

N2 - OBJECTIVES: The aim of the present study was to investigate if assymetric dimethylarginine (ADMA) is increased in patients with rheumatoid arthritis (RA) compared to healthy controls and to examine associations between ADMA, RA disease activity and in vivo assessments of microvascular and macrovascular endothelial function.METHODS: Sixty-seven RA patients (age [mean ± standard deviation]: 56 ± 12 years, disease duration median [25th-75th percentile]: 8 [3-15] years, 48 women) and 29 healthy controls (age [mean ± standard deviation]: 42 ± 12, 21 women) underwent assessments of microvascular endothelial function (Laser Doppler imaging with iontophoresis of acetylcholine and sodium-nitroprusside), and macrovascular endothelial function (flow-mediated dilatation and glyceryl-trinitrate-mediated dilatation) as well as arterial stiffness. ADMA levels were measured in contemporary specimens using an immunoassay ELISA kit.RESULTS: ADMA levels were significantly higher (p=0.004) in RA patients compared with healthy controls after adjustment for age (difference=0.088, 95% confidence interval 0.029-0.147). ADMA levels did not correlate with demographic or disease characteristics. No correlation was found between ADMA and microvascular and macrovascular endothelial function or with arterial stiffness.CONCLUSIONS: ADMA levels are increased in patients with RA but there was no significant correlation with in vivo assessments of endothelial function. Further studies are needed to unfold the pathophysiological role of nitric oxide/ADMA pathway derangement in endothelial dysfunction and cardiovascular risk in RA.

AB - OBJECTIVES: The aim of the present study was to investigate if assymetric dimethylarginine (ADMA) is increased in patients with rheumatoid arthritis (RA) compared to healthy controls and to examine associations between ADMA, RA disease activity and in vivo assessments of microvascular and macrovascular endothelial function.METHODS: Sixty-seven RA patients (age [mean ± standard deviation]: 56 ± 12 years, disease duration median [25th-75th percentile]: 8 [3-15] years, 48 women) and 29 healthy controls (age [mean ± standard deviation]: 42 ± 12, 21 women) underwent assessments of microvascular endothelial function (Laser Doppler imaging with iontophoresis of acetylcholine and sodium-nitroprusside), and macrovascular endothelial function (flow-mediated dilatation and glyceryl-trinitrate-mediated dilatation) as well as arterial stiffness. ADMA levels were measured in contemporary specimens using an immunoassay ELISA kit.RESULTS: ADMA levels were significantly higher (p=0.004) in RA patients compared with healthy controls after adjustment for age (difference=0.088, 95% confidence interval 0.029-0.147). ADMA levels did not correlate with demographic or disease characteristics. No correlation was found between ADMA and microvascular and macrovascular endothelial function or with arterial stiffness.CONCLUSIONS: ADMA levels are increased in patients with RA but there was no significant correlation with in vivo assessments of endothelial function. Further studies are needed to unfold the pathophysiological role of nitric oxide/ADMA pathway derangement in endothelial dysfunction and cardiovascular risk in RA.

KW - Adult

KW - Aged

KW - Arginine

KW - Arthritis, Rheumatoid

KW - Biomarkers

KW - Endothelium, Vascular

KW - Female

KW - Humans

KW - Male

KW - Microvessels

KW - Middle Aged

KW - Nitric Oxide

KW - Risk Factors

KW - Severity of Illness Index

KW - Vascular Diseases

KW - Vascular Stiffness

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

M3 - Article

VL - 30

SP - 388

EP - 396

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 3

ER -